<DOC>
	<DOCNO>NCT02470637</DOCNO>
	<brief_summary>Primary Objective : To assess dose-response pattern glucose consumption ( GIR-AUC0-end ) 3 different single dos Afrezza inhale Technosphere insulin 3 single dos subcutaneous ( SC ) insulin lispro euglycemic clamp set . Secondary Objectives : To assess dose proportionality insulin exposure ( INS-AUClast ) 3 different single dos Afrezza inhale Technosphere insulin 3 single dos SC insulin lispro euglycemic clamp set . To assess pharmacodynamic ( PD ) characteristics 3 different single dos Afrezza inhale Technosphere insulin 3 single dos SC insulin lispro euglycemic clamp set . To assess pharmacokinetic ( PK ) characteristics 3 different single dos Afrezza inhale Technosphere insulin 3 single dos SC insulin lispro euglycemic clamp set . To assess safety tolerability 3 different single dos Afrezza inhale Technosphere insulin .</brief_summary>
	<brief_title>Single Dose Clamp Study Evaluate Concentration-time Profile Metabolic Activity 3 Dose Levels Afrezza 3 Dose Levels Insulin Lispro Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The total study duration one patient approximately 6.7 22.7 week ( minimum maximum duration , exclude screen ) . The duration study include screening period 3 28 day ( D -28 D -3 ) , 6 treatment period 1 2 day ( 1 overnight stay ) , washout period 7 28 day ( preferentially 7 day consecutive dosing ) , end-of-study visit 7 14 day last study drug administration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Inclusion criterion : Male female patient , 18 65 year age , inclusive , diabetes mellitus type 1 one year , define American Diabetes Association . Total insulin dose &lt; 1.0 U/kg/day . Body weight 50.0 95 kg , inclusive , body mass index 18.5 29 kg/m² , inclusive . Fasting serum Cpeptide &lt; 0.3 nmol/L . Glycohemoglobin ( HbA1c ) ≤75 mmol/mol ( ≤9 % ) . Stable insulin regimen least 2 month prior study ( respect safety patient scientific integrity study ) . Certified otherwise healthy type 1 diabetes mellitus patient assessment medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , musculoskeletal system ) , unless Investigator considers abnormality clinically irrelevant interfere conduct study ( respect safety subject scientific integrity study ) . Having give write informed consent prior undertake studyrelated procedure . Nonsmoking least last 6 month screen ( confirm urine cotinine &lt; 500 µg/L ) . Pulmonary function test screening : forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) &gt; 70 % individual prediction accord equation Third National Health Nutrition Examination Survey ( NHANES III ) . Exclusion criterion : Severe hypoglycemia result coma/seizures require assistance another person , and/or hospitalization diabetic ketoacidosis last 6 month screen visit . Frequent severe headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . Presence history drug hypersensitivity , allergic disease diagnose treated physician . History presence drug alcohol abuse ( alcohol consumption 40 g per day ) . If female , pregnancy ( define positive betahuman chorionic gonadotropin [ βhCG ] blood test ) , breastfeed screen treatment period ( define positive βhCG urine test ) . Any medication ( include St John 's Wort ) within 14 day inclusion within 5 time elimination halflife PD halflife medication , exception insulin , thyroid hormone , lipidlowering , antihypertensive drug female exception hormonal contraception menopausal hormone replacement therapy ; vaccination within 28 day inclusion . Presence history acute chronic obstructive bronchopulmonary disease include chronic obstructive pulmonary disease , asthma , cancer . Upper respiratory tract infection within 8 week screen . Known hypersensitivity insulin lispro Afrezza Technosphere insulin excipients . Inability , opinion Principal Investigator designee , adequately inhale Afrezza powder . Any history presence deep leg vein thrombosis frequent appearance deep leg vein thrombosis firstdegree relative ( parent , sibling , child ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>